IN2012MN02262A - - Google Patents

Download PDF

Info

Publication number
IN2012MN02262A
IN2012MN02262A IN2262MUN2012A IN2012MN02262A IN 2012MN02262 A IN2012MN02262 A IN 2012MN02262A IN 2262MUN2012 A IN2262MUN2012 A IN 2262MUN2012A IN 2012MN02262 A IN2012MN02262 A IN 2012MN02262A
Authority
IN
India
Prior art keywords
multimeric protein
disclosed
protein structures
alpha
terms
Prior art date
Application number
Other languages
English (en)
Inventor
Avidor Shulman
Ilya Ruderfer
Tehila Ben-Moshe
Talia Shekhter
Yaniv Azulay
Yoseph Shaaltiel
Tali Kizhner
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of IN2012MN02262A publication Critical patent/IN2012MN02262A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
IN2262MUN2012 2010-03-02 2011-03-02 IN2012MN02262A (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (1)

Publication Number Publication Date
IN2012MN02262A true IN2012MN02262A (da) 2015-06-12

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2262MUN2012 IN2012MN02262A (da) 2010-03-02 2011-03-02

Country Status (23)

Country Link
EP (3) EP2542675B1 (da)
JP (2) JP5758920B2 (da)
KR (1) KR101928403B1 (da)
CN (1) CN102933707B (da)
AU (1) AU2011222452B2 (da)
BR (1) BR112012022029B1 (da)
CA (1) CA2791461C (da)
DK (1) DK2865751T3 (da)
ES (2) ES2708843T3 (da)
FI (1) FIC20230032I1 (da)
FR (1) FR23C1041I2 (da)
HR (1) HRP20200428T1 (da)
HU (2) HUE030959T2 (da)
IL (2) IL221741A (da)
IN (1) IN2012MN02262A (da)
NL (1) NL301249I2 (da)
NO (1) NO2023041I1 (da)
NZ (2) NZ623294A (da)
PL (1) PL2865751T3 (da)
SG (2) SG183558A1 (da)
SI (1) SI2865751T1 (da)
WO (1) WO2011107990A1 (da)
ZA (1) ZA201206725B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
DK2865751T3 (da) * 2010-03-02 2017-01-09 Protalix Ltd Stabiliseret alpha-galactosidase og anvendelser deraf
EP2665814B1 (en) * 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
AU2016232149B2 (en) 2015-03-17 2021-09-23 eleva GmbH Glycosylated lysosomal proteins, method of production and uses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
EP4321212A3 (en) * 2017-06-07 2024-05-15 Amano Enzyme Inc. Lactase bulk powder and lactase preparation
MY207075A (en) 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
TW202146648A (zh) * 2020-02-28 2021-12-16 美商克迪科思股份有限公司 人類α-半乳糖苷酶變異體
JP7833461B2 (ja) 2020-11-03 2026-03-19 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
MX2023005580A (es) * 2020-11-13 2023-05-29 Hanmi Pharmaceutical Co Ltd Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de enfermedades renales provocadas por o acompa?adas de la enfermedad de fabry.
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
US12703857B2 (en) 2023-02-02 2026-08-11 Protalix Ltd. Methods of treating diseases associated with elevated uric acid
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DK1009759T3 (da) * 1997-09-05 2008-08-04 Altus Pharmaceuticals Inc Carbohydrat-tværbundne glycoproteinkrystaller
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
CA2369869C (en) 1999-04-02 2008-06-10 Ajinomoto Co., Inc. Process for producing subunit peptide originating in polymer protein
DK1523548T3 (da) 2002-05-15 2010-05-10 Agricultural Res Org Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
JP4368925B2 (ja) * 2005-11-18 2009-11-18 財団法人 東京都医学研究機構 基質特異性を変換した新規高機能酵素
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
DK2865751T3 (da) * 2010-03-02 2017-01-09 Protalix Ltd Stabiliseret alpha-galactosidase og anvendelser deraf

Also Published As

Publication number Publication date
BR112012022029B1 (pt) 2022-10-11
EP2542675B1 (en) 2014-12-17
NL301249I2 (nl) 2023-12-14
ZA201206725B (en) 2013-06-26
PL2865751T3 (pl) 2017-03-31
JP5871999B2 (ja) 2016-03-01
SG183558A1 (en) 2012-10-30
EP3088514B1 (en) 2018-11-28
CN102933707B (zh) 2015-09-30
EP2865751B1 (en) 2016-09-14
EP2542675A1 (en) 2013-01-09
KR20130056216A (ko) 2013-05-29
SG10201502609QA (en) 2015-05-28
IL253249A (en) 2019-08-29
CA2791461A1 (en) 2011-09-09
NO2023041I1 (no) 2023-11-01
EP2865751A1 (en) 2015-04-29
ES2606532T3 (es) 2017-03-24
KR101928403B1 (ko) 2018-12-14
AU2011222452B2 (en) 2015-09-03
WO2011107990A1 (en) 2011-09-09
IL253249B (en) 2020-08-31
CN102933707A (zh) 2013-02-13
ES2708843T3 (es) 2019-04-11
EP3088514A1 (en) 2016-11-02
BR122014021216A2 (pt) 2021-06-01
RU2604795C2 (ru) 2016-12-10
BR112012022029A2 (pt) 2021-05-18
SI2865751T1 (sl) 2017-01-31
RU2012141651A (ru) 2014-04-10
HK1180720A1 (en) 2013-10-25
NZ623294A (en) 2015-10-30
HUS2300038I1 (hu) 2023-11-28
CA2791461C (en) 2019-10-22
FR23C1041I1 (da) 2023-12-29
DK2865751T3 (da) 2017-01-09
JP2014237694A (ja) 2014-12-18
NL301249I1 (da) 2023-11-08
IL221741A (en) 2017-07-31
FIC20230032I1 (fi) 2023-11-02
HUE030959T2 (en) 2017-06-28
JP2013520986A (ja) 2013-06-10
AU2011222452A1 (en) 2012-09-27
JP5758920B2 (ja) 2015-08-05
FR23C1041I2 (fr) 2024-08-02
HRP20200428T1 (hr) 2020-06-12
NZ602317A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
NZ602317A (en) Stabilized alpha-galactosidase and uses thereof
WO2011027222A3 (en) Immunogenic compositions including tlr activity modulators
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2012077950A3 (ko) 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
MX2012002654A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2013013013A3 (en) Compositions and methods for producing modified glycoproteins
MX367024B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
MY161127A (en) Enhanced soluble c5 saccharide yields
PH12015500243A1 (en) Glycoconjugation processes and compositions
JO3065B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
IN2012DN02645A (da)
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
WO2009129387A3 (en) Cationic lipids and uses thereof
WO2009135165A3 (en) Small humanin-like peptides
MX2017001898A (es) Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
WO2012064709A3 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
PH12013500143A1 (en) A method of treating alzheimer`s disease
WO2012004013A3 (en) Glucosinolate transporter protein and uses thereof